DE69407590D1 - Chemische-modifizierte oligonukleotide für site-spezifisches mutagenesis - Google Patents

Chemische-modifizierte oligonukleotide für site-spezifisches mutagenesis

Info

Publication number
DE69407590D1
DE69407590D1 DE69407590T DE69407590T DE69407590D1 DE 69407590 D1 DE69407590 D1 DE 69407590D1 DE 69407590 T DE69407590 T DE 69407590T DE 69407590 T DE69407590 T DE 69407590T DE 69407590 D1 DE69407590 D1 DE 69407590D1
Authority
DE
Germany
Prior art keywords
site
chemical
modified oligonucleotides
specific mutagenesis
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69407590T
Other languages
English (en)
Other versions
DE69407590T2 (de
Inventor
Peter Glazer
Pamela Havre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22176104&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69407590(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yale University filed Critical Yale University
Application granted granted Critical
Publication of DE69407590D1 publication Critical patent/DE69407590D1/de
Publication of DE69407590T2 publication Critical patent/DE69407590T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3511—Conjugate intercalating or cleaving agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69407590T 1993-06-25 1994-06-24 Chemische-modifizierte oligonukleotide für site-spezifisches mutagenesis Expired - Lifetime DE69407590T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8308893A 1993-06-25 1993-06-25
PCT/US1994/007234 WO1995001364A1 (en) 1993-06-25 1994-06-24 Chemically modified oligonucleotide for site-directed mutagenesis

Publications (2)

Publication Number Publication Date
DE69407590D1 true DE69407590D1 (de) 1998-02-05
DE69407590T2 DE69407590T2 (de) 1998-07-23

Family

ID=22176104

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69407590T Expired - Lifetime DE69407590T2 (de) 1993-06-25 1994-06-24 Chemische-modifizierte oligonukleotide für site-spezifisches mutagenesis

Country Status (9)

Country Link
US (1) US7078389B2 (de)
EP (1) EP0705270B1 (de)
JP (1) JPH09503644A (de)
AT (1) ATE161541T1 (de)
AU (1) AU691194B2 (de)
CA (1) CA2166079C (de)
DE (1) DE69407590T2 (de)
ES (1) ES2113118T3 (de)
WO (1) WO1995001364A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849482A (en) * 1988-09-28 1998-12-15 Epoch Pharmaceuticals, Inc. Crosslinking oligonucleotides
US6136601A (en) * 1991-08-21 2000-10-24 Epoch Pharmaceuticals, Inc. Targeted mutagenesis in living cells using modified oligonucleotides
US5962426A (en) 1993-06-25 1999-10-05 Yale University Triple-helix forming oligonucleotides for targeted mutagenesis
AU6043296A (en) * 1995-06-06 1996-12-24 Yale University Chemically modified oligonucleotide for site-directed mutage nesis
US7279463B2 (en) 1995-06-07 2007-10-09 Yale University Triple-helix forming oligonucleotides for targeted mutagenesis
US6124099A (en) * 1998-06-22 2000-09-26 The University Of Vermont And State Agricultural College Method for placing a photo-cross-linking agent at specific internal sites within the sequence of synthetic strands of ribonucleic acids
US7358090B2 (en) 2000-03-24 2008-04-15 The United States Of America As Represented By The Department Of Health And Human Services Establishment of cellular manipulations which enhance oligo-mediated gene targeting
FR2823219B1 (fr) * 2001-04-10 2003-07-04 Pasteur Institut Mutants de la desoxycytidine kinase possedant une activite enzymatique elargie
US8658608B2 (en) 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
DK3031919T3 (en) 2007-07-31 2019-01-07 Basf Enzymes Llc Tailored multi-site combination device
US20110268810A1 (en) * 2009-11-02 2011-11-03 Yale University Polymeric materials loaded with mutagenic and recombinagenic nucleic acids
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
EP3139909A4 (de) 2014-05-09 2018-01-03 Yale University Topische formulierung von hyperverzweigten polyglycerolbeschichteten partikeln
WO2017143042A2 (en) 2016-02-16 2017-08-24 Yale University Compositions for enhancing targeted gene editing and methods of use thereof
AU2017221424A1 (en) 2016-02-16 2018-09-20 Yale University Compositions and methods for treatment of cystic fibrosis
WO2018187493A1 (en) 2017-04-04 2018-10-11 Yale University Compositions and methods for in utero delivery
US20210189431A1 (en) 2018-08-10 2021-06-24 Yale University Compositions and methods for embryonic gene editing in vitro
KR20210054547A (ko) 2018-08-31 2021-05-13 예일 유니버시티 삼중체 및 뉴클레아제 기반 유전자 편집을 향상시키기 위한 조성물 및 방법
WO2020112195A1 (en) 2018-11-30 2020-06-04 Yale University Compositions, technologies and methods of using plerixafor to enhance gene editing
US20220372474A1 (en) 2019-06-21 2022-11-24 Yale University Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
US20220243211A1 (en) 2019-06-21 2022-08-04 Yale University Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof
US20220339294A1 (en) 2019-09-09 2022-10-27 Yale University Nanoparticles for selective tissue or cellular uptake

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792562A (en) 1985-12-04 1988-12-20 Hoechst-Roussel Pharmaceuticals, Inc. N-(pyrrol-1-yl)pyridinamines having memory enhancing activity
EP0266099A3 (de) * 1986-10-28 1990-09-19 The Johns Hopkins University Alkyl- oder Arylphosphonat-Oligonukleosid, das sich mit Nukleinesäuren vernetzen kann oder das Nukleinsäure spalten kann
CA2006008C (en) * 1988-12-20 2000-02-15 Donald J. Kessler Method for making synthetic oligonucleotides which bind specifically to target sites on duplex dna molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5962426A (en) * 1993-06-25 1999-10-05 Yale University Triple-helix forming oligonucleotides for targeted mutagenesis

Also Published As

Publication number Publication date
CA2166079C (en) 2009-11-17
DE69407590T2 (de) 1998-07-23
CA2166079A1 (en) 1995-01-12
JPH09503644A (ja) 1997-04-15
ATE161541T1 (de) 1998-01-15
ES2113118T3 (es) 1998-04-16
EP0705270B1 (de) 1997-12-29
US20020028922A1 (en) 2002-03-07
EP0705270A1 (de) 1996-04-10
WO1995001364A1 (en) 1995-01-12
AU691194B2 (en) 1998-05-14
US7078389B2 (en) 2006-07-18
AU7318094A (en) 1995-01-24

Similar Documents

Publication Publication Date Title
DE69407590T2 (de) Chemische-modifizierte oligonukleotide für site-spezifisches mutagenesis
Cheng et al. Monovalent cation effects on intermolecular purine-purine-pyrimidine triple-helix formation
Woese et al. Secondary structure model for bacterial 16S ribosomal RNA: phylogenetic, enzymatic and chemical evidence
Warpehoski et al. Sequence selectivity of DNA covalent modification
Cech et al. Secondary structure of the Tetrahymena ribosomal RNA intervening sequence: structural homology with fungal mitochondrial intervening sequences.
Wang et al. DNA supercoiling and its effects on DNA structure and function
Jones et al. Demography and phenology of gray whales and evaluation of whale-watching activities in Laguna San Ignacio, Baja California Sur, Mexico.
WO1996039195A3 (en) Chemically modified oligonucleotide for site-directed mutagenesis
Morgan et al. Rho-dependent termination of transcription. II. Kinetics of mRNA elongation during transcription from the bacteriophage lambda PR promoter.
Braaten et al. Locations and contexts of sequences that hybridize to poly (dG-dT).(dC-dA) in mammalian ribosomal DNAs and two X-linked genes
Murray et al. The sequence specificity of bleomycin-induced DNA damage in intact cells.
Elsholtz et al. A two-base change in a POU factor-binding site switches pituitary-specific to lymphoid-specific gene expression.
ES8605862A1 (es) Perfeccionamientos en las disposiciones para la deteccion desecuencias determinadas de nucleotidos, procedimiento de deteccion y de caracterizacion de una secuencia o de un fragmento de acido nucleico determinado y sonda clonad
DE69133329D1 (de) Markierte Oligonukleotide
ATE211769T1 (de) Oligonukleotide und verfahren zum nachweis von chlamydia trachomatis
DE3578786D1 (de) Als sonden zum nachweis von schaedlichen, in chromosom-dns enthaltenen genen zu verwendende deoxyribonukleinsaeuremolekuele.
ATE324464T1 (de) Eine in kaskaden verlaufende vervielfältigungsreaktion von nukleinsäuren
WO1999064582A3 (en) High-throughput screening of gene function using libraries for functional genomics applications
AU2379884A (en) Methods and structures employing non-radioactive chemically labelled polynucleotide probes
ZA853756B (en) Nucleic acid hybridization assay employing immobilized rna probes
ATE366822T1 (de) Verfahren zum quantitativen nachweis von nukleinsäuren
Galazka et al. Site-specific OsO4 modification of the BZ junctions formed at the (dA-dC) 32 region in supercoiled DNA.
Zito et al. Lead-catalyzed cleavage of ribonuclease P RNA as a probe for integrity of tertiary structure
Kang et al. Metal ions cause the isomerization of certain intramolecular triplexes.
ATE267879T1 (de) Polymerasesignalversuch

Legal Events

Date Code Title Description
8363 Opposition against the patent
8365 Fully valid after opposition proceedings